Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer

Cui,Hai‑Bin; Ge,Huai‑E; Bai,Xi‑Yong; Zhang,Wei; Zhang,Yuan‑Yuan; Wang,Juan; Li,Xing; Xing,Lian‑Ping; Guo,Sheng‑Hu; Wang,Zhi‑Yu

doi:10.3892/etm.2014.1599

May-2014 Volume 7 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2014 Volume 7 Issue 5

Full Size Image

Article Open Access

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer

Authors:
- Hai‑Bin Cui
- Huai‑E Ge
- Xi‑Yong Bai
- Wei Zhang
- Yuan‑Yuan Zhang
- Juan Wang
- Xing Li
- Lian‑Ping Xing
- Sheng‑Hu Guo
- Zhi‑Yu Wang
View Affiliations / Copyright

Affiliations: Department of Immunotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Oncology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China, Department of Pathology, University of Rochester, New York, NY 14642, USA
Pages: 1083-1088
|
Published online on: March 4, 2014

https://doi.org/10.3892/etm.2014.1599
Expand metrics +

Abstract

Neoadjuvant and hyperthermic intraperitoneal chemotherapies have been shown to be effective in the treatment of resectable advanced gastric cancer. The aim of the present study was to investigate the clinical efficiency and security of neoadjuvant chemotherapy in combination with hyperthermic intraperitoneal chemotherapy for the treatment of postoperative advanced gastric cancer. A total of 192 patients diagnosed with advanced gastric cancer were randomly divided into the following four groups (n=48 per group): Control, neoadjuvant chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and joint groups. The joint group received neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy. Complications, adverse reactions, recurrence rates within 2 years and the 1‑ and 3‑year survival rates following surgery were observed. No significant differences were observed in the occurrence rates of Ⅰ‑Ⅱ degree myelosuppression, Ⅲ‑Ⅳ degree myelosuppression, Ⅰ‑Ⅱ degree nausea or Ⅲ‑Ⅳ degree nausea and vomiting among the four groups (P>0.05). The median progression‑free survival times were 26, 31, 33 and 28 months in the control, neoadjuvant chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and joint groups, respectively (P<0.001). Compared with the control group, the recurrence‑free 2‑year survival rate of the joint group was significantly lower (P=0.04). The difference among the median survival times of the four groups was statistically significant (P=0.001). The 1‑year survival rate of the joint group was significantly higher when compared with the control group and the difference was statistically significant (P=0.03). However, no statistically significant difference was identified among the 1‑year survival rates of the four groups (P>0.05). Compared with the control group, the 3‑year survival rates of the other three groups were significantly higher (P<0.05). Therefore, the results of the present study indicated that neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy for the treatment of advanced gastric cancer is well tolerated and exhibits improved compliance and efficiency.

View Figures

View References

1	Yoshikawa T, Rino Y, Yukawa N, et al: Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 44:11–21. 2014. View Article : Google Scholar : PubMed/NCBI
2	Fujitani K: Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg. 30:119–129. 2013. View Article : Google Scholar : PubMed/NCBI
3	Webb CA, Weyker PD, Moitra VK and Raker RK: An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesth Analg. 116:924–931. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chen SS, Yang XC, Chi F, et al: A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma. Oncol Res. 20:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ahn HS, Lee HJ, Hahn S, et al: Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 116:5592–5598. 2010. View Article : Google Scholar
6	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
7	Zhu X and Li J: Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett. 1:407–412. 2010.PubMed/NCBI
8	Tsuburaya A, Nagata N, Cho H, et al: Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 71:1309–1314. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wang JP, Li CP and Chao Y: Hyperthermic intraperitoneal chemotherapy: another choice for advanced gastric cancer? J Chin Med Assoc. 76:415–416. 2013. View Article : Google Scholar : PubMed/NCBI
10	Tsilimparis N, Bockelmann C, Raue W, et al: Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 20:226–232. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chua YJ and Cunningham D: The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 14:2687–2690. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ychou M, Boige V, Pignon JP, et al: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29:1715–1721. 2011. View Article : Google Scholar
13	Hager ED, Dziambor H, Höhmann D, et al: Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer. 11(Suppl 1): 57–63. 2001. View Article : Google Scholar
14	Dicken BJ, Bigam DL, Cass C, et al: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 241:27–39. 2005.PubMed/NCBI
15	Nissan A, Stojadinovic A, Garofalo A, et al: Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. J Surg Oncol. 100:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bozzetti F, Yu W, Baratti D, et al: Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 98:273–276. 2008. View Article : Google Scholar : PubMed/NCBI
17	Huang JY, Xu YY, Sun Z, et al: Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 13:4379–4385. 2012. View Article : Google Scholar : PubMed/NCBI
18	Votanopoulos KI, Newman NA, Russell G, et al: Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 20:3497–3503. 2013.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles